pemetrexed + cisplatin

Phase 1/2Terminated

1 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Small Cell Lung Cancer

Conditions

Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC

Trial Timeline

Feb 1, 2007 → May 1, 2008

NCT ID

NCT00447421

About pemetrexed + cisplatin

pemetrexed + cisplatin is a phase 1/2 stage product being developed by Eli Lilly for Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00447421. Target conditions include Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC.

What happened to similar drugs?

20 of 20 similar drugs in Small Cell Lung Cancer were approved

Approved (20) Terminated (2) Active (0)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅Pemetrexed + CarboplatinEli LillyApproved

✅pemetrexedEli LillyApproved

✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved

✅DurvalumabAstraZenecaApproved

✅Gefitinib + DocetaxelAstraZenecaApproved

✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00040625	Pre-clinical	Completed	—	—	Mesothelioma
NCT01000480	Phase 2	Completed	Oct 1, 2009	Jul 1, 2013	Non Small Cell Lung Cancer
NCT00887549	Phase 2	Completed	Apr 1, 2009	Jun 1, 2011	Non-Small Cell Lung Cancer
NCT00895648	Phase 2	Terminated	Jan 1, 2009	Oct 1, 2012	Mesothelioma
NCT00475657	Phase 2	Terminated	Oct 1, 2007	Apr 1, 2008	Small Cell Lung Cancer
NCT00447421	Phase 1/2	Terminated	Feb 1, 2007	May 1, 2008	Small Cell Lung Cancer
NCT00415168	Phase 2	Completed	Dec 1, 2006	Jul 1, 2009	Gastric Cancer
NCT00386815	Phase 2	Completed	Oct 1, 2006	Feb 1, 2007	Malignant Pleural Mesothelioma
NCT00374868	Phase 1/2	Completed	Aug 1, 2006	Apr 1, 2008	Urologic Neoplasms
NCT00259285	Phase 2	Terminated	Nov 1, 2005	Dec 1, 2007	Non-Small-Cell Lung Cancer
NCT00251550	Phase 1/2	Completed	Oct 1, 2005	Aug 1, 2006	Malignant Pleural Mesotherioma
NCT00191308	Phase 2	Completed	May 1, 2005	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00320515	Phase 1/2	Completed	Mar 1, 2004	Jul 1, 2008	Neoplasm, Gastric
NCT00190801	Phase 2	Completed	Sep 1, 2003	Sep 1, 2005	Gastrointestinal Neoplasms
NCT00087698	Phase 2	Completed	Sep 1, 2003	Feb 1, 2008	Pleural Neoplasms

Competing Products

20 competing products in Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
mRNA-1769	Moderna	Phase 2	0
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	40
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Selpercatinib	Eli Lilly	Pre-clinical	26
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	40
NBTXR3	Nanobiotix	Phase 1/2	33
Pemetrexed	Eli Lilly	Pre-clinical	26
pemetrexed + erlotinib	Eli Lilly	Phase 2	35
LY3295668 Erbumine	Eli Lilly	Phase 1	29
FYB206 + FYB206 + Keytruda	Formycon AG	Phase 3	22
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	37
pemetrexed + cisplatin	Eli Lilly	Phase 2	27
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	35
Cetuximab	Eli Lilly	Phase 1	29
pemetrexed + docetaxel	Eli Lilly	Phase 3	40
enzastaurin + pemetrexed + docetaxel + carboplatin	Eli Lilly	Phase 2	35
PemCarbo + Pem only	Eli Lilly	Phase 3	36
TNG456 + abemaciclib	Eli Lilly	Phase 1/2	39